| abstract |
PROBLEM TO BE SOLVED: To provide an arginine deiminase having reduced cross-reactivity to an ADI-PEG20 antibody for cancer treatment. The present invention generally has reduced cross-reactivity with an anti-ADI-PEG20 antibody as compared to ADI-PEG20, but may have comparable or better functional properties to ADI-PEG20. It relates to an isolated arginine deiminase (ADI) protein, a composition comprising the ADI protein, and related methods for treating arginine-dependent or related diseases such as cancer. Embodiments of the present invention relate to selective ADI enzymes and in some embodiments are linked to PEG via a linker, eg, a stable linker. [Selection diagram] None |